Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.S*BIO, a biotech company engaged in research and clinical development of novel targeted small molecule drugs for the treatment of cancer, has dosed first 10 patients in a multi-center, open-label Phase 2 clinical trial of its novel JAK2 inhibitor SB1518 for the treatment of advanced lymphoid malignancies.
Subscribe to our email newsletter
The Phase 2 trial is designed to investigate the efficacy and safety of SB1518 in patients with advanced lymphoid malignancies.
In the trial, three patients demonstrated partial response and 15 patients maintained stable disease states.
The majority of the responses were sustained for greater than two months.
S*BIO CEO Jan-Anders Karlsson said the development of SB1518 in a second indication is a significant milestone in the clinical advancement of our lead JAK2 inhibitor.
"This trial closely follows our recent announcement of data from Phase 1/2 studies for SB1518 indicating its clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis and enlarged spleens," Karlsson said.